STRO
SUTRO BIOPHARMA, INC.
Next earnings Aug 5, 2026 · consensus $-2.58 EPS, $13.2M rev
Last earnings -3.0% on 2026-05-14
$30.52
▲ +3.28%$30.52▲ +281.07%
over 1Y
L $6.80EODHDH $40.91
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.3%
1W-3.3%
1M+2.8%
3M+24.9%
YTD+178.5%
1Y+281.1%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 20 analysts
Buy
Revenue grew 65.2% YoY; but unprofitable (net margin -186.5%).
SUTRO BIOPHARMA, INC. shows $102M in FY2025 revenue (+65.2% YoY), a -186.5% net margin.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $61.9M | $67.8M | $154M | $62.0M | $102M |
| Gross profit | — | — | — | — | — |
| Operating income | -$98.5M | -$129M | -$89.3M | -$238M | -$158M |
| Net income | -$106M | -$119M | -$107M | -$227M | -$191M |
| Diluted EPS | -$2.29 | -$2.35 | -$1.78 | -$29.40 | -$22.49 |
| Net margin | -170.6% | -175.9% | -69.5% | -366.6% | -186.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$452M
EV / EBITDA—
EV / Sales4.4
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-37.8%
FCF yield-35.4%
Quality & risk
ROIC (est.)—
Free cash flow-$179M
Total debt$4.06M
Net cash$54.1M
Altman Z-Score-8.78 distress
Piotroski F-Score4/8
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY-80.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — agreement terminated (2026-03-23). Worth a closer look.
Recent filings
all on EDGAR ↗4Period ending 2026-06-052026-06-09open ↗4Period ending 2026-06-052026-06-09open ↗4Period ending 2026-06-052026-06-09open ↗4Period ending 2026-06-052026-06-09open ↗4Period ending 2026-06-052026-06-09open ↗4Period ending 2026-06-052026-06-09open ↗4Period ending 2026-06-052026-06-09open ↗4Period ending 2026-06-052026-06-09open ↗8-KPeriod ending 2026-06-052026-06-08open ↗4Period ending 2026-06-022026-06-02open ↗SCHEDULE 13GFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗
Frequently asked
- Is SUTRO BIOPHARMA, INC. (STRO) a buy?
- STRO currently carries a Avoid rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 65.2% YoY; but unprofitable (net margin -186.5%).
- What is SUTRO BIOPHARMA, INC.'s quality score?
- STRO scores 43.52941176470588/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001382101, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 4:41:12 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.